Jupiter Bioscience Ltd Stock Analysis

BSE: 524826 | NSE: JUPITER | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Jupiter Bioscience

M-Cap below 100cr DeciZen not available

Jupiter Bioscience Price Chart

P/E Ratio ( SA) :
Market Cap :
24.8 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Jupiter Bioscience Ltd. a good quality company?

Data is not available for this company.

2. Is Jupiter Bioscience Ltd. undervalued or overvalued?

No data found

3. Is Jupiter Bioscience Ltd. a good buy now?

No data found

10 Year X-Ray of Jupiter Bioscience:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 23.2%17.4%14.2%11%10.9%8.8%8.4%7.4%7.2%5.6%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 54.561.665.670.879.9104130143184253168
YoY Gr. Rt. %-13.1%6.6%7.9%12.9%30.1%24.8%10.1%28.7%37.6%-
Adj EPS 15.816.517.21619.319.114.917.520.56-0.5
YoY Gr. Rt. %-4%4.3%-7%21%-1.3%-21.9%17.2%17.6%-70.7%-
BVPS (₹) 62.674.578.782.994.8120.2149.1172.6191.6116.1114.4
Adj Net Profit 1414.615.
Cash Flow from Ops. 11.116.525.921.928.215.642.758.469.788.7-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 18.6%25.9%24.9%37.6%
Adj EPS -10.2%-20.8%-26.1%-70.7%
BVPS 7.14.1-8-39.4
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 25.621.71915.215.813.311.699.56.4-0.4
Op. Profit Mgn % 37.138.7414343.843.64551.35243.439.2
Net Profit Mgn % 25.823.723.22021.418.120.819.71814.9-1.7
Debt to Equity
Working Cap Days 1661761641611802062412712472200
Cash Conv. Cycle 1391571511431491591771921751570

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Jupiter Bioscience Ltd.

Standalone Consolidated
TTM EPS (₹) -0.5 8.2
TTM Sales (₹ Cr.) 168 331
BVPS (₹.) 114.4 0
Reserves (₹ Cr.) 681 744
P/BV 0.03 0.00
PE 0.00 0.48
From the Market
52 Week Low / High (₹) 3.89 / 4.14
All Time Low / High (₹) 1.00 / 242.35
Market Cap (₹ Cr.) 24.8
Equity (₹ Cr.) 62.4
Face Value (₹) 10
Industry PE 33.7

Management X-Ray of Jupiter Bioscience :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *45.0545.0545.0545.0545.0645.0545.0545.0545.0545.05
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Jupiter Bioscience

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Jupiter Bioscience Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Jupiter Bioscience on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Jupiter Bioscience stood at ₹ 24.79.
The latest PE ratio of Jupiter Bioscience as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of Jupiter Bioscience as of 01-Jan-1970 05:30 is 0.03
The 52-week high of Jupiter Bioscience is ₹ 4.14 and the 52-week low is ₹ 3.89.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Jupiter Bioscience is ₹ 167.7 ( Cr.) .

About Jupiter Bioscience Ltd

Jupiter Bioscience is one of the few companies in the world to have competency in synthesis of peptides starting from the basic stage to finished peptides. The company was established in 1985 by K S Sarma a technocrat of repute and a respected entrepreneur in the Indian pharmaceutical industry. The company’s product portfolio further includes specialty and fine chemicals, drug intermediates, bulk drugs and nutraceuticals. With expertise on multiple technology platforms and processes based on advanced organic chemistry, chiral chemistry, peptide chemistry and biotechnology the company is geared to provide solutions for the global pharmaceutical and the biotechnology industry.


• 1985  Incorporated as a private limited company 

• 1987  Started commercial production of APIs 

• 1992  Backward integration for developing the key raw material 

• 1995  The company went public 

• 1997  Set up a new manufacturing facility for specialty chemicals & Intermediates 

• 1998  Commercialized the first indigenously developed peptide raw material 

• 2000  Floated a 100% subsidiary Sven Genetech to focus on Peptide chemistry, Chiral chemistry & Biotechnology 

• 2004  Commercialized processes for solution phase peptide synthesis 

• 2005  Commercialized processes for solid phase synthesis and production of unnatural amino acids 

• 2006  Acquisition of a manufacturing facility in Hyderabad 

• 2007  Strategic Alliance with Ranbaxy for Peptide APIs and formulations  

• 2008  Acquisition of a manufacturing facility in Switzerland


1. Peptide Building Blocks • Aminoacids and its Derivatives • Unnatural Aminoacids

2. Peptides • Peptides Overview • Pseudoproline Dipeptides • Peptide Coupling Reagents • Research Peptides • Generic Peptide APIs

3. Non-Peptide Generic Drugs & Intermediates • APIs for Human Use • Veterinary APIs • Drug Intermediates & Fine Chemicals

4. Under Development • Generic Peptide APIs • Biopharmaceuticals • Rapid Diagnostic Kit • Non-Peptide Generic APIs • Enzymes • Formulations • Peptide and DNA Microarrays


1. Custom Synthesis - Jupiter Bioscience offers custom manufacturing services for complex and challenging products to pharmaceutical industry and research Institutions.

2. Process Development & Scale Up - Jupiter undertakes process development and scale up on behalf of its customers in the areas of Organic Chemistry, Peptide chemistry, Chiral Chemistry and Biotechnology.

3. Contract R&D - The coming years will witness emergence of novel peptide drugs. Their dedicated research team comprising scientists from various disciplines can design peptide and peptide assemblies for specific molecular targets.


1. Sven Genetech Limited, India The company manufactures following category of products:

• Formulations

• Side chain protected amino acids and specialty peptides

• Un-natural amino acids and beta amino acids

• Enzymes

2. Jupiter Bioscience Inc, USA  The company is incorporated in USA in the state of Virginia. The company has a pharmaceutical manufacturing facility in the state of Maryland which is one of the manufacturing hubs for the pharmaceutical and the biotech sector in the US.

3. Jupiter Bioscience AG, Switzerland

The business segments of this subsidiary are:

• Custom synthesis of peptides and peptidomimetics • APIs for peptide in clinical trials by solid phase • Generic peptide APIs by solution phase

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now